key: cord-0981538-dptapovm
authors: Edara, Venkata-Viswanadh; Lai, Lilin; Sahoo, Malaya K.; Floyd, Katharine; Sibai, Mamdouh; Solis, Daniel; Flowers, Maria W.; Hussaini, Laila; Ciric, Caroline Rose; Bechnack, Sarah; Stephens, Kathy; Mokhtari, Elham Bayat; Mudvari, Prakriti; Creanga, Adrian; Pegu, Amarendra; Derrien-Colemyn, Alexandrine; Henry, Amy R.; Gagne, Matthew; Graham, Barney S.; Wrammert, Jens; Douek, Daniel C.; Boritz, Eli; Pinsky, Benjamin A.; Suthar, Mehul S.
title: Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
date: 2021-05-10
journal: bioRxiv
DOI: 10.1101/2021.05.09.443299
sha: 046954dc49d80078f7d99d94a0e492c837661b25
doc_id: 981538
cord_uid: dptapovm

SARS-CoV-2 has caused a devastating global pandemic. The recent emergence of SARS-CoV-2 variants that are less sensitive to neutralization by convalescent sera or vaccine-induced neutralizing antibody responses has raised concerns. A second wave of SARS-CoV-2 infections in India is leading to the expansion of SARS-CoV-2 variants. The B.1.617.1 variant has rapidly spread throughout India and to several countries throughout the world. In this study, using a live virus assay, we describe the neutralizing antibody response to the B.1.617.1 variant in serum from infected and vaccinated individuals. We found that the B.1.617.1 variant is 6.8-fold more resistant to neutralization by sera from COVID-19 convalescent and Moderna and Pfizer vaccinated individuals. Despite this, a majority of the sera from convalescent individuals and all sera from vaccinated individuals were still able to neutralize the B.1.617.1 variant. This suggests that protective immunity by the mRNA vaccines tested here are likely retained against the B.1.617.1 variant. As the B.1.617.1 variant continues to evolve, it will be important to monitor how additional mutations within the spike impact antibody resistance, viral transmission and vaccine efficacy.

Abstract 27 SARS-CoV-2 has caused a devastating global pandemic. The recent emergence of SARS-CoV-2 28 variants that are less sensitive to neutralization by convalescent sera or vaccine-induced 29 neutralizing antibody responses has raised concerns. A second wave of SARS-CoV-2 infections 30 in India is leading to the expansion of SARS-CoV-2 variants. The B.1.617.1 variant has rapidly 31 spread throughout India and to several countries throughout the world. In this study, using a live 32 virus assay, we describe the neutralizing antibody response to the B.1.617.1 variant in serum 33 from infected and vaccinated individuals. We found that the B.1.617.1 variant is 6.8-fold more 

Infection-and vaccine-induced antibody binding 110 and neutralization of the B.1.351 SARS-CoV-2 variant

Identification of SARS-CoV-2 spike mutations 112 that attenuate monoclonal and serum antibody neutralization

The variant 114 gambit: COVID-19's next move

Potent SARS-CoV-2 neutralizing antibodies directed 116 against spike N-terminal domain target a single supersite

Development of a Rapid Focus Reduction 118

Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

Convalascent Moderna (mRNA-1273)

This work was supported in part by grants (